Instead of an exclusive deal, Zymeworks shared its platform non-exclusively with multiple pharma giants. This multi-partner strategy validated the technology, generated capital, and built a portfolio of royalty interests before the company developed its own internal pipeline.

While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

Because their platform generates more high-potential drug targets than they can pursue internally, the company frames partnerships with large pharmaceutical firms as an ethical imperative. This approach ensures novel findings don't languish, allowing them to become life-saving drugs while triggering revenue sharing for their community partners.

A functional malaria vaccine was developed in the 1990s but took decades to reach patients. The delay was not scientific but economic; since it primarily affects poor nations, pharmaceutical companies had no profit motive to fund the necessary large-scale trials and distribution.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

The standard patent system, which rewards innovation through high prices, is inefficient for creating products for the poor like vaccines. Advanced Market Commitments (AMCs) solve this by creating a pull mechanism: a legally binding promise to buy a large quantity at a set price, guaranteeing a market and aligning incentives for innovation.

For pre-revenue biotechs like Voyager, partnering provides non-dilutive capital. More importantly, it de-risks development by sharing costs and leveraging a larger company's resources and expertise. This can increase a drug's probability of success, a crucial factor when most programs fail.

Selling low-cost vaccines to organizations like Gavi isn't just charity for pharmaceutical companies. It creates massive economies of scale, lowering the cost of goods for their high-margin primary markets and increasing overall net profit, creating a powerful win-win incentive structure.

For diseases affecting only the poorest populations, scientific success isn't enough. The key financial instrument is an "advanced purchase" guarantee from a government or large organization. This de-risks production for manufacturers, providing a viable business model where traditional profit motives fail.